US2009281022A1PendingUtilityA1

Method for Producing Factor VII Glycoforms

Assignee: NOVO NORDISK HEALTHCARE AGPriority: Oct 2, 2000Filed: Jul 15, 2009Published: Nov 12, 2009
Est. expiryOct 2, 2020(expired)· nominal 20-yr term from priority
A61P 7/04A61K 38/00G01N 2400/02C12N 9/6437C12Y 304/21021A61K 38/4846C12P 21/02A61K 38/16
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Claims

exact text as granted — not AI-modified
1 . A method for large-scale production of Factor VII or a Factor VII-related polypeptide, comprising the steps of:
 (i) propagating a large-scale culture of mammalian cells in medium lacking animal-derived components until the large-scale culture cells reach a second predetermined density, said large-scale culture having been created by a method comprising:
 inoculating mammalian cells expressing Factor VII or a Factor VII-related polypeptide into a seed culture vessel containing medium lacking animal-derived components; 
 propagating the inoculated cells at least until the cells have reached a first predetermined density to form a seed culture, 
 transferring the seed culture to a large-scale culture vessel containing medium lacking animal derived components to form said large-scale culture; 
   (ii) maintaining the large-scale culture in medium lacking animal-derived components under conditions appropriate for Factor VII expression, thereby causing the cells to produce Factor VII or a Factor VII-related polypeptide, and   (iii) recovering the produced Factor VII or Factor VII-related polypeptide from the maintained culture.   
     
     
         2 . A method as defined in  claim 1 , wherein said cells are CHO cells. 
     
     
         3 . A method as defined in  claim 1 , wherein said Factor VII has a glycosylation pattern different from both Factor VII produced in vivo and Factor VII produced in BHK cells. 
     
     
         4 . A method as defined in  claim 1 , wherein said seed culture has been transferred to and propagated in one or more intermediate size vessels of progressively larger size prior to being transferred to said large scale vessel. 
     
     
         5 . A method as defined in  claim 1 , wherein the cells have been rendered suspension culture competent prior to being inoculated into the seed vessel. 
     
     
         6 . A method as defined in  claim 1 , wherein the cells have been adapted to grow in medium lacking animal-derived components prior to said inoculation. 
     
     
         7 . A method as defined in  claim 1 , wherein the large-scale culture is a macrocarrier culture. 
     
     
         8 . A method as defined in  claim 7 , wherein the large-scale culture is a macroporous carrier culture, said macroporous carrier bearing a positive charge. 
     
     
         9 . A method as defined in  claim 1 , wherein the maintaining step comprises regularly harvesting a portion of the supernatant of said large-scale culture and replacing it with fresh medium lacking animal-derived components. 
     
     
         10 . A method as defined in  claim 1 , wherein the maintaining step comprises sedimentation of the cell-containing carriers prior to said harvesting. 
     
     
         11 . A method as defined in  claim 1 , wherein the maintaining step comprises cooling the culture to a pre-determined temperature before the sedimentation. 
     
     
         12 . A method as defined in  claim 1 , wherein the maintaining step comprises feeding said cells with glucose. 
     
     
         13 . A method as defined in  claim 12 , wherein feeding comprises pulse feeding from 1 to 4 times per 24-hour period. 
     
     
         14 . A method as defined in  claim 12 , wherein said feeding comprises gradual or continuous introduction of glucose into the large scale culture. 
     
     
         15 . A method for large-scale production of Factor VII or a Factor VII-related polypeptide, comprising the steps of:
 (i) maintaining a large-scale culture of mammalian cells having a second predetermined density in medium lacking animal-derived components under conditions appropriate for Factor VII expression, thereby causing the cells to produce Factor VII or a Factor VII-related polypeptide, said large-scale culture having been created by a method comprising:
 inoculating mammalian cells expressing Factor VII or a Factor VII-related polypeptide into a seed culture vessel containing medium lacking animal-derived components; 
 propagating the inoculated cells at least until the cells have reached a first predetermined density to form a seed culture, 
 transferring the seed culture to a large-scale culture vessel containing medium lacking animal derived components to form said large-scale culture; and 
   (ii) recovering produced Factor VII or Factor VII-related polypeptide from the maintained culture.   
     
     
         16 . A method for large-scale production of Factor VII or a Factor VII-related polypeptide, comprising the steps of:
 (i) maintaining a large-scale culture of mammalian cells having a second predetermined density in medium lacking animal-derived components under conditions appropriate for Factor VII expression, thereby causing the cells to produce Factor VII or a Factor VII-related polypeptide, said large-scale culture having been created by a method comprising:
 inoculating mammalian cells expressing Factor VII or a Factor VII-related polypeptide into a seed culture vessel containing medium lacking animal-derived components; 
 propagating the inoculated cells at least until the cells have reached a first predetermined density to form a seed culture, and 
   (ii) transferring the seed culture to a large-scale culture vessel containing medium lacking animal derived components to form said large-scale culture.   
     
     
         17 . A Factor VII or Factor VII-related polypeptide produced by a method as defined in  claim 1 . 
     
     
         18 . A Factor VII or Factor VII-related polypeptide produced by a method as defined in  claim 15 . 
     
     
         19 . A Factor VII or Factor VII-related polypeptide produced by a method as defined in  claim 16 . 
     
     
         20 . A preparation comprising a plurality of Factor VII or Factor VII-related polypeptides expressed by recombinant BHK or CHO cells in the presence of media lacking animal-derived components (serum-free Factor VII), wherein the Factor VII or Factor VII-related polypeptides comprise N-linked oligosaccharides chains and the oligosaccharides exhibit a glycoform pattern differing from that of the same Factor VII or Factor VII-related polypeptide expressed by the same cells in the presence of serum (serum-raised Factor VII) and from that of Factor VII purified from human plasma (native Factor VII) and wherein a percentage of oligosaccharide chains in said preparation comprise at least one sialic acid moiety, said percentage being higher than that observed in serum-raised Factor VII preparations and lower than the corresponding percentage in native Factor VII preparations, said serum-free Factor VII preparation having a higher bioavailability than the bioavailability of a serum-raised Factor VII preparation.

Join the waitlist — get patent alerts

Track US2009281022A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.